Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy by Bekő, Gabriella et al.
DOI 10.1515/cclm-2012-0485      Clin Chem Lab Med 2012; x(x): xxx–xxx
 Gabriella  Bek ő ,  Henriett  Butz ,  Kl á ra  Berta ,  Andr á s  Tisl é r ,  Ferenc  Olajos ,  Barna  V á s á rhelyi 
and  Attila  Pat ó cs* 
 Switching between parathormone (PTH) 
assays: the impact on the diagnosis of renal 
osteodystrophy 
 Abstract 
 Background: Clinical guidelines for decision-making in 
chronic kidney disease (CKD) consider parathormone 
(PTH) levels. The measured PTH values differ if novel full 
length PTH(1-84) assays are used instead of earlier intact 
iPTH assays. In this study we analyzed how the classifica-
tion of CKD patients alters when iPTH assays are switched 
to PTH(1-84) assays. 
 Methods: Plasma samples were collected prior to dialy-
sis sessions from 110 consecutive CKD patients on main-
tenance hemodialysis. PTH levels were determined with 
iPTH assays (Elecsys, Architect and DiaSorin Liaison 
N-tact) and PTH(1-84) assays (Elecsys and Liaison). Using 
KDIGO guidelines patients were classified as being below, 
above and in the recommended target range (RTR) of PTH. 
The results of classification with different assays were 
evaluated and, a novel calculation method of RTR was 
implemented. 
 Results: The prevalence of patients with PTH in RTR is 
comparable with each assay, but the individual patients 
differed. PTH(1-84) Elecsys and Liaison assays classified 
more patients as being below RTR than iPTH Elecsys and 
Architect but not Liaison N-tact assay (27.3%, 22.7% vs. 
41%, 31.8%, and 36.4%, respectively). In turn, PTH(1-84) 
Elecsys and Liaison assays identified less CKD patients 
with PTH above the RTR than iPTH except N-tact assays 
(6.4%, 10% vs. 16.3%, 19%, and 6.3%, respectively). Using 
our calculation method, our discrimination values for 
PTH(1-84) assays to achieve classification identical to that 
with iPTH Elecsys were lower than those recommended by 
the manufacturer. 
 Conclusions: Current guidelines for the treatment of sec-
ondary hyperparathyroidism in CKD should consider the 
type of assays used for PTH measurement. Each labora-
tory should assess its own RTR for PTH tests to achieve 
comparable classification. The presented calculation is 
simple, it mimics an everyday situation, switching from 
one assay to another one, and provides useful RTR values 
for PTH tests. 
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 Introduction 
 Parathyroid hormone or parathormone (PTH) is an 84 
amino acid-long polypeptide hormone produced in 
parathyroid glands. Its blood level is regulated mainly 
by blood ionized calcium concentration with low extra-
cellular calcium levels promoting (1-84)PTH secretion. 
An important point of regulation is the enhanced prote-
olysis of (1-84)PTH. Although N-terminal PTH fragments 
are traditionally considered to be inactive, the C termi-
nal fragmented (7 – 84)PTH molecules may inhibit PTH 
action [ 1 ]. 
 PTH levels are routinely measured to monitor the 
progression of secondary hyperparathyroidism (sHPT) 
in patients with chronic kidney disease (CKD). Several 
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preanalytical and analytical factors affect the results of 
PTH analysis [ 2 – 4 ]. The method used for PTH detection 
also affects PTH results. Up to a 2.7- to 4-fold difference 
in PTH values were reported with different assays when 
samples of CKD patients or lyophilized pools of plasma 
distributed by the UK National External Quality Assess-
ment Service (UK NEQAS) were measured repeatedly [ 3 ]. 
Inaccurate measurement of PTH may lead to misclassi-
fication of patients and result in inadequate therapeutic 
decisions [ 5 ]. 
 UK National Institute for Health and Clinical Excel-
lence (NICE) guidelines contain recommendations for 
therapy of sHPT in patients who have either uncontrolled 
or unresponsive PTH plasma levels and who are not candi-
date for parathyroidectomy [ 3 ]. Therapeutic interventions 
both from Kidney Disease: Improving Global Outcomes 
(KDIGO) [ 6 ] and Renal Association [ 7 ] guidelines recom-
mended PTH recommended target ranges (RTR) for hemo-
dialyzed CKD patients. Novel guidelines replaced the exact 
numeric values (i.e., 150 – 300 pg/mL) (K-DOQI, 2003) for 
RTR to 2ULN and 9ULN (upper level of the healthy normal 
reference) [ 6–9 ]. All these recommendations and guide-
lines are based on PTH measurements performed with 
2nd generation assays are generally referred to as  ‘ intact ’ 
PTH assays (iPTH). The limitation of iPTH assays is their 
cross-reaction with C terminal fragmented ( 7- 84)PTH mol-
ecules which may accumulate in patients with CKD [ 10 ]. 
Novel PTH assays referred to as 3rd generation PTH assays 
[PTH(1-84)] (sometimes also called  ‘ whole ’ or  ‘ bioactive ’ 
PTH assays) have been developed and increasingly recom-
mended for routine diagnostic purposes [ 6 ]. These assays 
exclusively detect the whole (1-84)PTH molecules. While 
levels measured with iPTH and PTH(1-84) assays generally 
correlate, PTH(1-84) assays usually provide results 40% –
 50% lower than iPTH assays [ 11 ,  12 ]. Therefore, reference 
intervals are affected by these novel assays. However, 
current guidelines have not fully incorporated this tech-
nological development and 3rd generation assays may 
not be optimal for classification of CKD patients based on 
current guidelines [ 13 – 19 ]. 
 A PTH standardization meeting in September, 2010 
[ 16 ] drafted the determination of assay-specific RTR as an 
outstanding priority in order to select the optimal medical 
therapy for SHPT in patients with CKD. These recommen-
dations highlighted that switching from one PTH assay to 
another might be more difficult for PTH than for any other 
analyte. In order to establish reference values and also 
RTR values for PTH, samples from healthy, 25-OH-vitamin 
D-replete individuals are needed. 
 In the present study we evaluated and compared PTH 
levels measured by two novel 3rd generation PTH(1-84) 
assays and three 2nd generation iPTH assays. We compared 
their classification performance in a hemodyalized CKD 
population and we implemented a calculation method for 
determination of RTRs which provided similar classifica-
tion of patients to those measured with iPTH assay. 
 Materials and methods 
 We used plasma samples collected from 110 patients [55 women, 55 
men, age: (mean ± SD) 56.6 ± 14.7, range: 24 – 90 years] with CKD on he-
modialysis years on treatment: 4.4 ± 4 years (mean ± SD). 
 Determination of PTH levels 
 Blood was obtained before dialysis sessions in cooled EDTA tubes. 
Tubes were centrifuged within 30 min of sampling, then aliquoted 
and stored at  – 80 ° C until use. Two 3rd generation assays detecting 
the whole (1-84)PTH Roche Elecsys PTH(1-84) REF:05608546 190 and 
Liaison PTH(1-84) REF:13597 and three 2nd generation iPTH assays 
(Roche Elecsys iPTH REF:11972103 122, Abbott Architect iPTH REF: 
8K25 and LIAISON N-TACT PTH II assay REF: 310660) were used. As-
say characteristics provided by the manufacturers are summarized 
in  Table 1 . All assays were performed according to manufacturers in-
structions at the Central Laboratory of the Department of Laboratory 
Medicine, Semmelweis University. This study was approved by the 
Local Institutional Ethical Committee. 
 Statistical analysis 
 Statistical analysis was performed using SPSS v 19. soft ware pack-
age. Data are expressed as mean ± standard deviation. The compari-
sons between diff erent groups were performed with Student ‘ s paired 
t-test. Correlations between diff erent PTH assays were determined 
using parametric Pearson ‘ s correlation. A p-value of  < 0.05 was con-
sidered to be signifi cant. 
 Based on 2ULN and 9ULN of each assays provided by the manu-
facturers, we classifi ed our patients whether they are below, within 
or above the PTH RTR. Receiver operating characteristics curve (ROC) 
was used for calculation of our own RTR for the novel PTH(1-84) as-
says in order to ensure the classifi cation comparable to that with 
Elecsys iPTH. 
 Results 
 Analytical comparison of different PTH 
assays 
 In general, average PTH(1-84) levels for the whole patient 
group were about 33% – 51% lower than iPTH levels were 
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[Elecsys PTH(1-84) 149 ± 119 pg/mL and Liaison PTH(1-84) 
127 ± 114 pg/mL vs. Elecsys IPTH; 288 ± 247 pg/mL; Archi-
tect iPTH 333 ± 278 pg/mL and Liaison N-tact 224.3 ± 203 pg/
mL, p < 0.001]. 
 Despite these large differences in absolute values 
strong correlations were detected between each test as R 2 
values ranged between 0.76 and 0.981. The lowest R 2 value 
was obtained when Liaison N-tact assay was compared to 
others. 
 Effect of ULNs on classification of CKD 
patients 
 Using ULNs provided by the manufacturers, 52.7% – 58.2% 
of patients were within PTH RTR ( Table 2 ). However, a 
large portion of these patients was not identical. 
 The next step was to evaluate how switching to the 
3rd generation PTH(1-84) assays would affect individual 
patient ‘ s classification. As a result of switching from iPTH 
 Manufacturer  iPTH assays  PTH( 1 -84) assays 
 Elecsys PTH  Architect iPTH  N-tact Liaison PTH  Elecsys PTH( 1 -84)  Liaison-PTH ( 1 -84)  
  REF:11972103 122  REF: 8K25  REF:310660  REF:05608546 190  REF:13597
 Method principle  ECLIA  CMIA  CLIA  ECLIA  CLIA 
 Range of measurement, 
pg/mL 
 1.2 – 5000  3.0 – 3000  2.0 – 2000  5.5 – 2300  1.7 – 1800 
 Intra-assay CV, %  1.5 – 4.1  4.1 – 9  3.9 – 6.1  1.6 – 7.4   ≤  6 
 Inter-assay CV, %  2.6 – 6.5  3 – 6.4  5.1 – 8.9  3.1 – 9.4   ≤  9 
 Antibodies used in the 
assay 
 Monoclonal mouse 
(26 – 32) 
 Polyclonal goat  Polyclonal goat 
 ( 1 – 34) 
 Polyclonal goat 
 (39 – 84) 
 Monoclonal mouse 
(54–59) 
 Polyclonal (C-terminal) 
Polyclonal (N-terminal) 
 (amino acid epitopes)  Monoclonal mouse 
(37 – 42) 
 Polyclonal goat  Monoclonal mouse 
( 1 – 5 ) 
 
 Healthy reference range  15 – 65  15 – 68  11.7 – 61.1  15 – 57  5.5 – 38 
 Table 1  Analytical parameters of PTH assays used. 
 CLIA, chemiluminescence immunoassay; CMIA, chemiluminescence microparticle immunoassay; CV, variation of coefficient; ECLIA, 
electrochemiluminescence immunoassay; ULN, upper limit of normal. 
  PTH RTR based on 
ULNs provided by 
the manufacturer 
 Patients number (%) 
below RTR ( < 2 ULN 
of PTH) 
 Patient number 
(%) within RTR 
(2 – 9 ULN of PTH) 
 Patient number (%) 
above RTR ( > 9 ULN 
of PTH) 
 iPTH (2nd generation) assays 
  iPTH Elecsys  130 – 585 pg/mL  30 (27.3%)  62 (56.4%)  18 (16.3%) 
  iPTH Architect  136 – 615 pg/mL  25 (22.7%)  64 (58.2%)  21 (19%) 
  iPTH N-tact Liaison  146 – 656 pg/mL  40 (36.4%)  63 (57.3%)  7 (6.3%) 
 PTH( 1 -84) (3rd generation) assays 
  Elecsys PTH( 1 -84)  114 – 512 pg/mL  45 (41%)  58 (52.7%)  7 (6.4%) 
  Liaison PTH( 1 -84)  77 – 346 pg/mL  35 (31.8%)  64 (58.2%)  11 (10%) 
 Number of patients (%) with altered classification when novel PTH( 1 -84) (3rd generation) assays are used instead of iPTH Elecsys test 
  Elecsys PTH( 1 -84)  114 – 512 pg/mL  + 15 (13.7%)  – 4 ( – 3.7%)  – 11 ( – 9.9%) 
  Liaison PTH( 1 -84)  77 – 346 pg/mL  + 5 (4.8%)  + 2 ( + 1.8%)  – 7 ( – 6.3%) 
 Number of patients (%) with altered classification when novel PTH( 1 -84) (3rd generation) assays are used instead of iPTH Architect tests 
  Elecsys PTH( 1 -84)  114 – 512 pg/mL  + 20 (18.2%)  – 6 ( – 5.4%)  – 14 ( – 12.7%) 
  Liaison PTH( 1 -84)  77 – 346 pg/mL  + 10 (9.1%)  0  – 10 ( – 9.1%) 
 Number of patients (%) with altered classification when novel PTH( 1 -84) (3rd generation) assays are used instead of iPTH N-tact Liaison test 
  Elecsys PTH( 1 -84)  114 – 512 pg/mL  + 5 ( + 4.5%)  – 5 ( – 4.5%)  0 
  Liaison PTH( 1 -84)  77 – 346 pg/mL  – 5 ( – 4.5%)  + 1 ( + 0.9%)  + 4 ( + 3.6%) 
 Table 2  Classification of chronic kidney disease (CKD) patients based on KDIGO guideline [see ref. [ 6 ] in text] using PTH recommended 
target range (RTR) based on upper limits of normal (ULN) provided by the manufacturers and number of patient misclassified when novel 
PTH ( 1 -84) are used instead of iPTH assays. 
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  Sensitivity 
with 
manufacturers ’ 
ULN values 
 Specificity 
with 
manufacturers ’ 
ULN values 
 Sensitivity 
with our 
calculated 
ULN values 
 Specificity 
with our 
calculated 
ULN values 
 Elecsys PTH( 1 -84) vs. Elecsys iPTH assay 
  2 ULN  80  100  96.3  96.7 
  9 ULN  39  100  94  100 
 Elecsys PTH( 1 -84) vs. Architect iPTH assay 
  2 ULN  76.5  100  92  96 
  9 ULN  33  100  81  99 
 Elecsys PTH( 1 -84) vs. Liaison N-tact assay 
  2 ULN  93.3  68  86.7  88 
  9 ULN  100  94  100  98 
 Liaison PTH( 1 -84) vs. Elecsys iPTH assay 
  2 ULN  88.8  100  96.3  97.3 
  9 ULN  66.7  98.9  94.4  98.8 
 Liaison PTH( 1 -84) vs. Architect iPTH assay 
  2 ULN  84  100  91.8  100 
  9 ULN  57  99  81  98 
 Liaison PTH( 1 -84) vs. Liaison N-tact assay 
  2 ULN  93.3  68  95  58 
  9 ULN  100  94.4  100  89 
 Table 3   At 100% specificity for KDIGO classification, the sensitivity 
of different PTH( 1 -84) assays based on manufacturers ’ ULNs and the 
specificity and sensitivity of classification using our calculated ULN 
values, respectively. ULN, upper limit of normal. 2ULN and 9ULN are 
discrimination levels recommended by KDIGO guideline. 
Elecsys to Elecsys PTH(1-84), the PTH of 10% of patients 
classified originally as above RTR became within RTR and 
14% of patients classified originally as within RTR became 
below RTR. Similar tendencies were observed with any 
other switch from any iPTH to PTH(1-84) assay (Table 2) 
except when Liaison PTH(1-84) assay was used instead of 
Liaison N-tact assay. In this later case only 3.6% of patients 
were classified differently (Table 2). Using the ULNs pro-
vided by the manufacturers the sensitivity of 3rd generation 
PTH(1-84) assays ranged between 33% and 88.8% ( Table 
3 ). Cavalier et al. has published other RTR values for all of 
the three iPTH assays and for Liaison PTH(1-84), respec-
tively (Supplemental data, Table 1, which accompanies the 
article at  http://www.degruyter.com/view/j/cclm.2013.51.
issue-6/issue-files/cclm.2013.51.issue-6.xml ). Therefore, we 
compared how these ULNs would affect the classification of 
our patients. By using their ULNs the classification showed 
very similar results to those obtained by using manufactur-
ers ‘ ULNs (Supplementary  Table 1 ,  Table 4 and  Figure 1 ). 
 Determination of novel RTR values 
 By using ROC curves, we calculated those ULNs that would 
provide similar classification when PTH is measured by 
Elecsys PTH(1-84) and Liaison PTH(1-84) assays. We used 
classification results with Elecsys iPTH test as reference. 
For both PTH(1-84) assays the calculated ULNs were lower 
compared to those provided by manufacturers ( Table 4 ). 
Using our RTR values in all switching types except when 
Liaison N-tact would be changed to Liaison PTH(1-84), 
better classification was obtained. In addition, our RTRs 
performed better than those provided by Cavalier et al 
(Table 4, Figure 1). However, neither of the Cavalier ’ s RTRs 
performed well when the switch was from Liaison N-tact 
to Liaison PTH(1-84) assay. 
 Discussion 
 In our current study we modeled a common everyday situ-
ation in clinical chemistry when a PTH assay is replaced 
by another one. We compared the impact of switching 
on sHPT classification of CKD patients according to the 
recent KDIGO guideline. 
 Our results confirmed that iPTH levels measured by 
Architect are higher than those measured by Elecsys iPTH 
[ 20 ] and that PTH levels measured with 3rd generation 
PTH assays are about half of those measured with iPTH 
assays [ 16 ,  19 ]. Using manufacturers ’ ULNs the clinical 
classification is altered in up to 23% of CKD patients as the 
result of switch. However, the Liaison N-tact PTH assay 
which is a 2nd generation iPTH test showed very similar 
classification characteristics to those obtained by 3rd gen-
eration assays. 
 Using ROC analysis and using Elecsys iPTH assay as a 
reference we established the new RTR for PTH(1-84) assays 
in order to provide the same classification. As any labora-
tory who intend to switch from one assay to another one 
has the data already measured, our approach would allow 
RTRs to be established with similar classification prop-
erties to those provided by the prior assay. In our study 
with these new RTRs the classification based on PTH(1-84) 
differs just in 1.8% – 7.3% of total cases classified accord-
ing to iPTH levels. Of note, the manufacturer provided 
RTR for Liaison PTH(1-84) assay resulted in less misclas-
sified patients when the PTH measurement was initially 
performed with iPTH Liaison N-tact assay. This result may 
suggest that a smoother switch can be obtained when 
the newer generation of assays is chosen from the same 
manufacturer. 
 It has been demonstrated that the KDIGO guideline 
using ULNs instead of exact numbers is superior to the 
earlier K-DOQI guideline where 150 pg/mL, 300 pg/mL 
and 800 pg/mL iPTH values were defined as therapeutic 
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 Figure 1   Percentage of patients misclassified when novel PTH(1-84) assays are used instead of Elecsys iPTH. 
  PTH RTR based on 
our and Cavalier ’ s 
results 
 Patients number 
(%) below RTR 
( < 2 ULN of PTH) 
 Patient number 
(%) within RTR 
(2 – 9 ULN of PTH) 
 Patient number (%) 
above RTR ( > 9 ULN 
of PTH) 
 PTH( 1 -84) (3rd generation) assays 
  Elecsys PTH( 1 -84) by our RTR  85 – 258 pg/mL  32 (29%)  55 (50%)  23 (21%) 
  Liaison PTH( 1 -84) by our RTR  67 – 288 pg/mL  33 (30%)  58 (52.7%)  19 (17.3%) 
  Liaison PTH( 1 -84) by Cavalier et al.  52 – 232 pg/mL  20 (18.2%)  62 (56.4%)  28 (25.4%) 
 Number of patients (%) with altered classification when novel PTH( 1 -84) (3rd generation) assays are used instead of iPTH Elecsys test 
  Elecsys PTH( 1 -84) by our RTR  85 – 258 pg/mL  + 2 ( + 1.8%)  – 7 ( – 6.8%)  + 5 ( + 4.8%) 
  Liaison PTH( 1 -84) by our RTR  67 – 288 pg/mL  + 3 ( + 2.7%)  – 4 ( – 3.6%)  + 1 ( + 0.9%) 
  Liaison PTH( 1 -84) by Cavalier et al.  52 – 232 pg/mL  – 10 ( – 9.1%)  0  + 10 (9.1%) 
 Number of patients (%) with altered classification when novel PTH( 1 -84) (3rd generation) assays are used instead of iPTH Architect tests 
  Elecsys PTH( 1 -84) by our RTR  85 – 258 pg/mL  + 7 ( + 6.3%)  – 9 ( – 8.2%)  + 2 (1.8%) 
  Liaison PTH( 1 -84) by our RTR  67 – 288 pg/mL  + 8 ( + 7.3%)  – 6 ( – 5.4%)  – 2 ( – 1.8%) 
  Liaison PTH( 1 -84) by Cavalier et al.  52 – 232 pg/mL  – 5 ( – 4.8%)  – 2 ( – 1.8%)  + 7 ( + 6.3%) 
 Number of patients (%) with altered classification when novel PTH( 1 -84) (3rd generation) assays are used instead of iPTH N-tact Liaison test 
  Elecsys PTH( 1 -84) by our RTR  85 – 258 pg/mL  – 8 ( – 7.3%)  – 8 ( – 7.3%)  + 16 (15.5%) 
  Liaison PTH( 1 -84) by our RTR  67 – 288 pg/mL  – 7 ( – 6.3%)  – 5 ( – 4.8%)  + 12 ( + 11%) 
 Table 4  Classification of chronic kidney disease (CKD) patients based on KDIGO guideline using PTH recommended target range (RTR) 
based on upper limits calculated by receiver operator characteristics (ROC) analysis and based on data provided by Cavalier et al. [see ref. 
[ 19 ] in text] and number of patients misclassified when novel PTH ( 1 -84) are used instead of iPTH assays. 
decision points [ 17 ]. The benefit of KDIGO guideline is 
the minimization of discrepancies resulting from the ana-
lytical performances of different assays and the establish-
ment of assay-independent therapeutic decision limits. 
Our RTR for Liaison PTH(1-84) assay is comparable to 
those published by Cavalier et al. in a healthy population 
[ 19 ], and is close to that of Ca-PTH(1-84) IRMA assay. RTR 
for Liaison and Elecsys PTH(1-84) assays in our study were 
65 and 68 pg/mL, and 258 and 288 pg/mL, vs. previously 
published 52 pg/mL and 62 pg/mL, and 232 pg/mL and 
277 pg/mL, respectively. These results confirm that the 
RTR suggested by KDIGO guideline cannot be calculated 
from those ULN that manufacturers provide as a reference 
range for PTH(1-84) levels. 
 Any switch between PTH assays should be performed 
carefully. Additionally, to the analytical validation the 
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laboratory should establish its own RTR used for clinical 
decision-making in CKD. Our analysis highlights that RTR 
based on ULNs provided by manufacturers is insufficient 
for this purpose as it may lead misclassification in a sig-
nificant portion of patients, if earlier iPTH assays are used 
as reference. 
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